Ascletis Pharma Inc.
HKSE: 1672.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jinzi Jason Wu
- Employees
- 231
- Headquarters
- Hangzhou, China
- IPO year
- 2018
- Market cap
- HK$17.9B
- Website
- https://www.ascletis.com
Loading 1672…
Loading profile data…Frequently asked questions about 1672
What does Ascletis Pharma Inc. (1672.HK) do?
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved or...
Where does 1672.HK trade?
Ascletis Pharma Inc. (1672.HK) trades on the Hong Kong Stock Exchange.
What sector is 1672.HK in?
Ascletis Pharma Inc. (1672.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ascletis Pharma Inc.?
Jinzi Jason Wu is the chief executive officer of Ascletis Pharma Inc. (1672.HK).
Where is Ascletis Pharma Inc. headquartered?
Ascletis Pharma Inc. is headquartered in China.
Does 1672.HK pay a dividend?
Ascletis Pharma Inc. (1672.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1672.HK go public?
Ascletis Pharma Inc. (1672.HK) completed its initial public offering in 2018.